Breast Cancer – Unmet Need – Unmet Need – Metastatic Triple-Negative Breast Cancer (US/EU)

The treatment of metastatic triple-negative breast cancer is rapidly evolving with new combination therapies and biomarker-driven approaches. Immunotherapies such as Keytruda (Merck & Co.) have reshaped first-line treatment, while the PARP inhibitor Lynparza (AstraZeneca) offers a targeted option for BRCA-mutated patients. Antibody drug conjugates such as Trodelvy (Immunomedics) are expanding later-line options for heavily pretreated patients. Despite these advances, significant clinical opportunity remains, particularly in improving survival outcomes and addressing safety concerns. This Unmet Need report provides insights into physicians’ prescribing behaviors, their perception of key targeted therapies, current gaps in treatment, and how emerging therapies can capitalize on these opportunities.

Questions answered

• What are the key factors that drive medical oncologists’ prescribing decisions for metastatic triple-negative breast cancer?
• How do oncologists evaluate the performance of existing metastatic triple-negative breast cancer therapies across key clinical and nonclinical factors such as efficacy, safety, and convenience of administration?
• What are the most significant gaps in the metastatic triple-negative breast cancer treatment landscape?
• What trade-offs are oncologists willing to make between clinical attributes (e.g., overall survival, toxicity profile) and price when selecting a treatment regimen?

Geography: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European medical oncologists

Key drugs covered: Keytruda, Tecentriq, Avastin, Lynparza, Talzenna, Trodelvy, Halaven

Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.